申请人:Eli Lilly and Company
公开号:US06239135B1
公开(公告)日:2001-05-29
A series of aryl piperazine compounds of the formula:
or the pharmaceutically acceptable salts thereof, are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
一系列芳基哌嗪化合物的化学式为:或其药用可接受的盐,对于治疗与或受到5-羟色胺1A受体相关的疾病条件非常有效;这些化合物特别是该受体的拮抗剂,并且特别适用于缓解尼古丁和烟草戒断症状。